Granulocyte colony-stimulating factor: Molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis

https://spiral.imperial.ac.uk/bitstream/10044/1/23497/2/Cell%20Stem%20Cell%2c%204%281%29%2c%202009.pdf

Differential Mobilization of Subsets of Progenitor Cells from the Bone Marrow

Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: A systematic review and meta-analysis of randomized controlled trials

Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction: A Meta-Analysis

The ability to exploit angiogenesis and vascularization as a therapeutic strategy will be of enormous benefit to a wide range of medical and tissue-engineering applications. Angiogenic growth factor and cell-based therapies have thus far failed to produce a robust healing response in clinical trials for a variety of ischemic diseases, while engineered tissue substitutes are still size-limited by a lack of vascularization. The purpose of this review is to investigate current research advances in therapeutic vascularization strategies applied to ischemic disease states, tissue engineering and regenerative medicine. Recent advances are discussed that focus on better regulation of growth factor delivery and attempts to better mimic natural processes by delivering combinations of multiple growth factors, cells and bioactive materials in the right spatial and temporal setting. Some unconventional approaches and novel therapeutic targets that hold significant potential are also discussed.

/pdf/update-on-therapeutic-vascularization-strategies-231xho2svs.pdf

Update on therapeutic vascularization strategies

Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial

Based upon substantial preclinical testing, we initiated an FDA-sanctioned, single-site dose escalation study of granulocyte colony stimulation factor (G-CSF) to attempt to enhance myocardial healing for patients with large acute MI via mobilization of stem cells. Principal inclusion criteria were age ≤80 yrs, acute ST elevation MI reperfused late (4–48 h), EF 20–39%, and coronary anatomy unlikely to require CABG. Patients were randomized to G-CSF or placebo in a 2:1 fashion and treated for 5 days starting

Kelly J. Brezina

Papers

Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial

First human randomized trial of G-CSF stem cell mobilization to treat large acute myocardial infarction—preliminary results of a pilot study